The result of the study by Fleischmann et al. indicates that, the allocation of FLT3-ITD to different cellular compartments and targeting distinct downstream signaling might represent a new therapeutic strategy to overcome resistance towards tyrosine kinase inhibitors in FLT3-ITD AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.